

## Supplementary material

Journal: Clinical Drug Investigation

Title: Safety assessment of liver injury with Quetiapine fumarate XR management in very heavy drinking alcohol dependent patients

**Author List:** <sup>†1,5</sup>Vatsalya Vatsalya, MD PgD MSc MS; <sup>1</sup>Hridgandh Donde PhD; <sup>2</sup>Aakash Pandey MD; <sup>3</sup>Melanie L. Schwandt, PhD; <sup>1</sup>Matthew C. Cave MD; <sup>1,4</sup>Shirish S. Barve PhD; <sup>5\*</sup>Vijay A Ramchandani PhD; <sup>1,4,6\*</sup>Craig J. McClain, MD

### Authors Affiliation:

<sup>1</sup>Department of Medicine, University of Louisville School of Medicine, Louisville KY USA

<sup>2</sup>Department of Pediatric Gastroenterology, Maria Fareri Children's Hospital - Westchester Medical Center, Valhalla NY USA

<sup>3</sup>Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda MD USA

<sup>4</sup>Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville KY USA

<sup>5</sup>Section on Human Psychopharmacology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda MD USA

<sup>6</sup>Robley Rex VA Medical Center, Louisville KY USA

Supplement Figure 1. Evaluation of liver injury by incidence and level of elevated ALT values in patients at each assessment timeline during the study period in quetiapine and placebo arm. "Total" shows records included in the study from the baseline number of participants at each study phase. Data presented as Mean  $\pm$  Standard Error. Q: in Quetiapine treatment group. P: in Placebo treatment group. ALT normal range: 6 – 40 IU/L. Gr.1: Non-elevated group from baseline. Gr.2: Elevated group from baseline.

